You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMesoridazine
Accession NumberDB00933  (APRD00610)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine antipsychotic with effects similar to chlorpromazine. [PubChem]
Structure
Thumb
Synonyms
10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine
10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine
2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine
Mesoridazina
Mesoridazine
Mesoridazinum
Thioridazine Thiomethyl Sulfoxide
thioridazine-2-sulfoxide
TPS-23
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Serentil Tab 10mgTablet10 mgOralNovartis Pharmaceuticals Canada Inc1970-12-312000-08-02Canada
Serentil Tab 25mgTablet25 mgOralNovartis Pharmaceuticals Canada Inc1997-08-292001-07-30Canada
Serentil Tab 50mgTablet50 mgOralNovartis Pharmaceuticals Canada Inc1997-08-292001-07-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LidanarNot Available
LidanilNot Available
SerentilNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mesoridazine besylate
ThumbNot applicableDBSALT001396
Mesoridazine mesilate
ThumbNot applicableDBSALT001073
Categories
UNII5XE4NWM740
CAS number5588-33-0
WeightAverage: 386.574
Monoisotopic: 386.148654844
Chemical FormulaC21H26N2OS2
InChI KeySLVMESMUVMCQIY-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
2-methanesulfinyl-10-[2-(1-methylpiperidin-2-yl)ethyl]-10H-phenothiazine
SMILES
CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
Pharmacology
IndicationUsed in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.
Structured Indications Not Available
PharmacodynamicsMesoridazine, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer. Pharmacological studies in laboratory animals have established that mesoridazine has a spectrum of pharmacodynamic actions typical of a major tranquilizer. In common with other tranquilizers it inhibits spontaneous motor activity in mice, prolongs thiopental and hexobarbital sleeping time in mice and produces spindles and block of arousal reaction in the EEG of rabbits. It is effective in blocking spinal reflexes in the cut and antagonizes d-amphetamine excitation and toxicity in grouped mice. It shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-hydroxytryptamine in vivo. Intravenously administered, it lowers the blood pressure of anesthetized dogs. It has a weak antiacetylcholine effect in vitro.
Mechanism of actionBased upon animal studies, mesoridazine, as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. In addition, the phenothiazines exhibit at least part of their activities through depression of hypothalamic centers. Neurochemically, the phenothiazines are thought to exert their effects by a central adrenergic blocking action.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding4%
MetabolismNot Available
Route of eliminationNot Available
Half life24 to 48 hours
ClearanceNot Available
ToxicityOral LD50 is 560 ± 62.5 mg/kg and 644 ± 48 mg/kg in mouse and rat, respectively. Symptoms of overdose may include emesis, muscle tremors, decreased food intake and death associated with aspiration of oral-gastric contents into the respiratory system.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineMesoridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMesoridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Mesoridazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Mesoridazine can be increased when it is combined with Abiraterone.Approved
AcebutololMesoridazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mesoridazine.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Mesoridazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mesoridazine.Approved, Illicit, Investigational
AlprenololMesoridazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Amantadine.Approved
AmiodaroneThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Mesoridazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amperozide.Experimental
AmphetamineMesoridazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Aop200704Mesoridazine may increase the hypotensive activities of Aop200704.Investigational
ApomorphineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aripiprazole.Approved, Investigational
ArotinololMesoridazine may increase the hypotensive activities of Arotinolol.Approved
ArtemetherThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Mesoridazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Mesoridazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Asenapine.Approved
AtenololMesoridazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Mesoridazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Mesoridazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Azaperone.Vet Approved
AzelastineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.Illicit
BefunololMesoridazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzocaine.Approved
BenzphetamineMesoridazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Mesoridazine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe serum concentration of Mesoridazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololMesoridazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideMesoridazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololMesoridazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololMesoridazine may increase the hypotensive activities of Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brotizolam.Approved, Withdrawn
BucindololMesoridazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolMesoridazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mesoridazine.Approved, Investigational
BupranololMesoridazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Mesoridazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Mesoridazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mesoridazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mesoridazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mesoridazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mesoridazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carisoprodol.Approved
CarteololMesoridazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolMesoridazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Mesoridazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMesoridazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mesoridazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Mesoridazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorphenamine.Approved
ChlorphentermineMesoridazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Mesoridazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Mesoridazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Mesoridazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Mesoridazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mesoridazine.Approved, Vet Approved
CitalopramThe metabolism of Mesoridazine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Mesoridazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clidinium.Approved
ClobazamThe metabolism of Mesoridazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Mesoridazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mesoridazine.Approved, Illicit
ClotrimazoleThe metabolism of Mesoridazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Mesoridazine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Mesoridazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Mesoridazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mesoridazine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Mesoridazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Mesoridazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Mesoridazine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Mesoridazine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desflurane.Approved
DesipramineThe metabolism of Mesoridazine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mesoridazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mesoridazine.Approved, Vet Approved
DextroamphetamineMesoridazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Mesoridazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mesoridazine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Mesoridazine.Approved, Illicit, Vet Approved
DiethylpropionMesoridazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Difenoxin.Approved, Illicit
DihydroartemisininThe serum concentration of Mesoridazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mesoridazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Mesoridazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Mesoridazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Mesoridazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Illicit
DronedaroneThe metabolism of Mesoridazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Mesoridazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Mesoridazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mesoridazine.Approved, Investigational
EliglustatThe metabolism of Mesoridazine can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Mesoridazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mesoridazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mesoridazine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.Approved, Investigational
EsmololMesoridazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mesoridazine.Approved
EthanolMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mesoridazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Mesoridazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mesoridazine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mesoridazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mesoridazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Mesoridazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Mesoridazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Mesoridazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Mesoridazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe metabolism of Mesoridazine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Hexobarbital.Approved
HydrocodoneMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine.Approved, Illicit
Hydroxyamphetamine hydrobromideMesoridazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Mesoridazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Iloperidone.Approved
ImipramineThe metabolism of Mesoridazine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indalpine.Investigational, Withdrawn
IndenololMesoridazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Mesoridazine can be decreased when combined with Indinavir.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mesoridazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mesoridazine.Approved, Vet Approved
IsoniazidThe metabolism of Mesoridazine can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Mesoridazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolMesoridazine may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levetiracetam.Approved, Investigational
LevobunololMesoridazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mesoridazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mesoridazine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Mesoridazine.Approved, Investigational
LisdexamfetamineMesoridazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Mesoridazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Mesoridazine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mesoridazine.Approved
LorcaserinThe metabolism of Mesoridazine can be decreased when combined with Lorcaserin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mesoridazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Mesoridazine is combined with Lu AA21004.Investigational
LumefantrineThe serum concentration of Mesoridazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Mesoridazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Melperone.Approved
MephedroneMesoridazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineMesoridazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.Approved, Illicit
MequitazineMesoridazine may increase the arrhythmogenic activities of Mequitazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Metaxalone.Approved
MethadoneThe metabolism of Mesoridazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMesoridazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Mesoridazine.Approved
MethotrimeprazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mesoridazine.Approved
MetipranololMesoridazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.Approved, Investigational
MetoprololThe metabolism of Mesoridazine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineMesoridazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MirabegronThe metabolism of Mesoridazine can be decreased when combined with Mirabegron.Approved
MirtazapineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Mesoridazine can be increased when it is combined with Mizoribine.Investigational
MMDAMesoridazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mesoridazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mesoridazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
NadololMesoridazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mesoridazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Mesoridazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mesoridazine.Approved, Withdrawn
NevirapineThe metabolism of Mesoridazine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Mesoridazine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Mesoridazine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mesoridazine.Approved
OpiumThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Opium.Approved, Illicit
OrphenadrineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mesoridazine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mesoridazine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mesoridazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Mesoridazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Mesoridazine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMesoridazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mesoridazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mesoridazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mesoridazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mesoridazine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenoxyethanol.Approved
PhentermineMesoridazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pimozide.Approved
PindololMesoridazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.Approved
PractololMesoridazine may increase the hypotensive activities of Practolol.Approved
PramipexoleMesoridazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mesoridazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Mesoridazine.Approved
PrimaquineThe serum concentration of Mesoridazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mesoridazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Mesoridazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.Approved, Vet Approved
ProguanilThe serum concentration of Mesoridazine can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Mesoridazine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mesoridazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Propoxycaine.Approved
PropranololMesoridazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Mesoridazine is combined with PSD502.Investigational
PseudoephedrineMesoridazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Mesoridazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Mesoridazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Mesoridazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Mesoridazine.Approved
QuinidineThe metabolism of Mesoridazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Mesoridazine can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Mesoridazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Mesoridazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mesoridazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mesoridazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mesoridazine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ritanserin.Investigational
RitobegronMesoridazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Mesoridazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Mesoridazine.Approved
RolapitantThe metabolism of Mesoridazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Romifidine.Vet Approved
RopiniroleMesoridazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine.Approved
RotigotineMesoridazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mesoridazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Mesoridazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Mesoridazine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mesoridazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mesoridazine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Mesoridazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sevoflurane.Approved, Vet Approved
SinefunginThe serum concentration of Mesoridazine can be increased when it is combined with Sinefungin.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
SotalolMesoridazine may increase the hypotensive activities of Sotalol.Approved
StiripentolThe metabolism of Mesoridazine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.Approved, Investigational
SulfadoxineThe serum concentration of Mesoridazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Mesoridazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Mesoridazine.Approved, Investigational
SuvorexantMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Mesoridazine can be increased when it is combined with tafenoquine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Mesoridazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Mesoridazine.Approved
TerbinafineThe metabolism of Mesoridazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mesoridazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrodotoxin.Investigational
ThalidomideMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Mesoridazine can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Mesoridazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiletamine.Vet Approved
TimololMesoridazine may increase the hypotensive activities of Timolol.Approved
TipranavirThe metabolism of Mesoridazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mesoridazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Mesoridazine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Mesoridazine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mesoridazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Mesoridazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Mesoridazine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mesoridazine.Approved, Investigational
VenlafaxineThe metabolism of Mesoridazine can be decreased when combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vilazodone.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Mesoridazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mesoridazine.Approved, Investigational
ZolpidemMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation.
References
Synthesis Reference

DrugSyn.org

US3084161
General ReferencesNot Available
External Links
ATC CodesN05AC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9322
Blood Brain Barrier+0.9863
Caco-2 permeable+0.5609
P-glycoprotein substrateSubstrate0.7284
P-glycoprotein inhibitor IInhibitor0.8978
P-glycoprotein inhibitor IIInhibitor0.5334
Renal organic cation transporterInhibitor0.7467
CYP450 2C9 substrateNon-substrate0.7962
CYP450 2D6 substrateNon-substrate0.5465
CYP450 3A4 substrateSubstrate0.5561
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5635
Ames testNon AMES toxic0.6982
CarcinogenicityNon-carcinogens0.8829
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.7465 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7565
hERG inhibition (predictor II)Inhibitor0.762
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0767 mg/mLALOGPS
logP3.83ALOGPS
logP3.57ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)19.36ChemAxon
pKa (Strongest Basic)8.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity115.13 m3·mol-1ChemAxon
Polarizability43.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9331000000-8e14cb597ee411174c3eView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Piperidine
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699 ]
  3. Choi S, Haggart D, Toll L, Cuny GD: Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4379-82. [PubMed:15357957 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Choi S, Haggart D, Toll L, Cuny GD: Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4379-82. [PubMed:15357957 ]
  2. Rauser L, Savage JE, Meltzer HY, Roth BL: Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther. 2001 Oct;299(1):83-9. [PubMed:11561066 ]
  3. Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):226-32. [PubMed:10991983 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23